Phenotypes Associated with This Genotype

Genotype
MGI:4868475

• Allelic Composition: Del(10Prmt2-Col6a1)1Yah/+
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

growth/size/body

growth/size/body region phenotype ( J:167506 )

N • growth and weight are normal

behavior/neurological

behavior/neurological phenotype ( J:167506 )

N • normal geotaxic righting response

N • horizontal and vertical activity in an open field test are normal

N • Y-maze behavior normal

N • normal balance

N • spatial working memory is normal

hematopoietic system

decreased hematocrit ( J:167506 )

• slightly reduced

increased red blood cell distribution width ( J:167506 )

• slightly

abnormal macrophage physiology ( J:167506 )

• TNF alpha levels in macrophage increase after lipopolysaccharide treatment relative to controls

• NO levels in macrophage increase after both lipopolysaccharide and bacterial lipoprotein treatment relative to controls

respiratory system

abnormal respiratory system physiology ( J:167506 )

• attenuated airway response to intranasal administration of lipopolysaccharide

respiratory system inflammation ( J:167506 )

• bronchoaveolar fluid is higher in neutrophiles after intranasal administration of lipopolysaccharide than is true of controls

lung inflammation ( J:167506 )

• increased myeloperoxidase activity in lungs

• enhanced recruitment of inflammatory cells in lungs and alveoli

immune system

abnormal macrophage physiology ( J:167506 )

• TNF alpha levels in macrophage increase after lipopolysaccharide treatment relative to controls

• NO levels in macrophage increase after both lipopolysaccharide and bacterial lipoprotein treatment relative to controls

abnormal cytokine level ( J:167506 )

• increased levels in bronchoalveolar fluid 24 hours after intranasal administration of lipopolysaccharide

• systemic levels increased as well after peritoneal administration of lipopolysaccharide

respiratory system inflammation ( J:167506 )

• bronchoaveolar fluid is higher in neutrophiles after intranasal administration of lipopolysaccharide than is true of controls

lung inflammation ( J:167506 )

• increased myeloperoxidase activity in lungs

• enhanced recruitment of inflammatory cells in lungs and alveoli

homeostasis/metabolism

abnormal cytokine level ( J:167506 )

• increased levels in bronchoalveolar fluid 24 hours after intranasal administration of lipopolysaccharide

• systemic levels increased as well after peritoneal administration of lipopolysaccharide